The antiparasitic drugs ivermectin and fenbendazole cure cancer, and the medical establishment is hiding it

Why it spread, and why the distrust is real

It would be a mistake to treat the people drawn to this as gullible. The belief grows in the hardest soil there is, and several of the things feeding it are legitimate. A cancer diagnosis is one of the most frightening events in a life, and conventional treatment can be grueling and uncertain. Against that, a cheap, off-patent pill that promises to work gently has an obvious and human appeal, and the idea that it is being kept from you offers both hope and a place to aim the fear.

The distrust also has a specific, recent history. Ivermectin spent the pandemic as a symbol in a bitter fight over whose medical authority to believe, and for millions of people that fight ended with a settled conviction that experts had misled them and dismissed a cheap drug out of arrogance or bad faith. Whatever one makes of that history, it left a large audience primed to believe the next chapter, and the cancer claim slotted neatly into a story they already held.

The preclinical studies are real, the podcasts are persuasive, and the grief is bottomless. That is why this spreads faster than a footnote about clinical trials ever could.

Then there is the machinery of how it travels. The claim has a sympathetic founder in Joe Tippens, a businessman who says a dog dewormer saved his life; it has celebrity oxygen, as when Mel Gibson told Joe Rogan's enormous audience that ivermectin cured three friends; and it has the raw persuasive force of before-and-after testimony. Within weeks of that podcast, online conversation about the drugs for cancer reportedly jumped by nearly 200 percent. Set a real published lab study, a moving personal story, and a famous voice against a careful explanation of why mouse data rarely translates, and it is no mystery which one wins the scroll. The grievances are real and deserve a serious answer, not a sneer, before the claim itself is weighed.

The Joe Tippens case, and the missing detail

Almost every version of the fenbendazole story traces back to one man. In 2018 Joe Tippens, an Oklahoma businessman, was diagnosed with small-cell lung cancer that had spread widely, and given a bleak prognosis. On a tip he says came from a veterinarian, he began taking fenbendazole, the dog dewormer, along with vitamin E and curcumin. His cancer went into complete remission, he wrote about it on a blog, and the “Joe Tippens protocol” was born and spread across the world.

There is a detail that the viral retellings tend to leave out, and it changes the story entirely. At the same time, Tippens was enrolled in a clinical trial of pembrolizumab, sold as Keytruda, an FDA-approved immunotherapy that unleashes the immune system against tumors. Checkpoint inhibitors like pembrolizumab are precisely the class of drug known to produce dramatic, durable remissions in a subset of patients. A striking response in someone receiving one is not a mystery demanding a dewormer to explain it; it is the immunotherapy doing the thing immunotherapy is famous for.

This is the oldest trap in medicine: two things happened together, so the more surprising one gets the credit. When a patient takes an unproven remedy on top of a powerful real treatment and then improves, the remedy collects the praise while the treatment that likely did the work is forgotten. Oncologists see the pattern constantly. It is the single reason controlled trials, which compare like with like and can tell which ingredient mattered, are the standard of proof, and why one vivid anecdote with an obvious alternative explanation cannot be.

What the evidence and the authorities say

Strip away the anecdote and ask the plain question: has anyone shown, in a proper trial, that these drugs treat cancer in people? The answer is no. No completed, controlled clinical trial has demonstrated that ivermectin or fenbendazole is safe and effective against any human cancer. The evidence that exists is preclinical (cells and mice) and anecdotal (testimonials, many from patients also receiving real treatment). Neither kind can establish that a therapy works, which is why the entire apparatus of clinical trials was built.

The professional bodies have said so directly. In May 2026 the American Society of Clinical Oncology issued a formal clinical notice recommending against using ivermectin or fenbendazole to treat cancer, or as an add-on to established therapy, outside a well-designed clinical trial. It pointed to the lack of robust peer-reviewed evidence of benefit and to real risks: toxicity and harmful interactions with cancer drugs. The American Cancer Society says the same in plain terms, that the drugs are not approved to treat cancer and no guideline recommends them. This is not a fringe dismissal; it is the settled view of mainstream oncology, arrived at in the open.

The suppression narrative struggles against a simple fact. Ivermectin is being tested against cancer right now, openly. A randomized phase II trial known as ICONIC, pairing ivermectin with immune-checkpoint inhibitors in solid tumors, is registered publicly on ClinicalTrials.gov, and earlier ivermectin results were presented at an ASCO meeting. If the drugs were being buried, they would not be the subject of registered trials, conference presentations, and dozens of published papers. Non-commercial researchers, charities, and universities with no profit motive would gain enormous prestige from proving a cheap cure works, and would announce it the moment they had it. What is missing is not the will to test; it is a positive result in humans.

And the “nothing to lose” framing is the most dangerous part. Both drugs can injure the liver; ivermectin at high or repeated doses has caused neurological harm, and one reported patient following social-media dosing developed confusion, drowsiness, and acute kidney injury. Fenbendazole was never tested for human safety at all. Worst of all is the harm that leaves no trace in a lab report: the patients who put their faith in a pill and let a treatable cancer advance. In an aggressive disease, the weeks lost can be the whole game.